Applications

1686 – 177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

177 Lutetium PSMA i&t is a targeted radionuclide radiotherapy that enters the cancer cell via the PSMA receptor, which is overexpressed in prostate cancer, with expression increasing in metastatic and castrate resistant disease. Therapy is intended for patients with progressive metastatic castrate resistant prostate cancer after the disease has progressed despite chemotherapy. Screening with PSMA Positron Emission Tomography (PET) and FDG PET determines if the patient has an adequate level of PSMA ‘target’ at all sites of measurable disease such that they will be expected to derive significant benefit from the treatment.

Type: Therapeutic technology

Medical condition this application addresses

Prostate cancer is one of the commonest cancers in Australia. Castrate-resistant prostate cancer is defined by disease progression despite androgen depletion therapy (reducing the amount of testosterone in the body) and may present as either a continuous rise in serum prostate-specific antigen levels (usually elevated in men with prostate cancer), the progression of pre-existing disease, and/or the appearance of new metastases.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 10 June 2022

Meetings to consider this application

  • PASC meeting: 9–10 December 2021
  • ESC meeting: 9–10 June 2022
  • MSAC meeting: 28–29 July 2022